JPMorgan initiates Eikon Therapeutics stock at Overweight
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices jump 2% amid widening US-Israel conflict with Iran Asia stocks slide as US-Iran strikes batter risk appetite Oil prices surge after US-Israel strikes on Iran, trim early gains Middle East tensions rise as Iran promises retaliation (South Africa Philippines Nigeria) JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com Analyst Ratings Published 03/02/2026, 02:55 AM JPMorgan initiates Eikon Therapeutics stock at Overweight 0 EIKN 1.03% Investing.com - JPMorgan initiated coverage on Eikon Therapeutics Inc. (NASDAQ:EIKN) with an Overweight rating and set a price target of $29.00, analyst Brian Cheng said Monday. The target represents significant upside from the current stock price of $13.78, which trades near its 52-week low of $13.29. The firm highlighted the company’s portfolio, led by former Keytruda developers, which includes two advanced assets through in-licenses and a pipeline built from its super resolution microscopy discovery engine. The TLR7/8 agonist EIK1001 is positioned to move beyond current immunotherapy regimens in lung cancer and melanoma, supported by Phase 2 efficacy data for the combination therapy. Two pivotal Phase 2/3 trials are underway, positioning the portfolio as a late-stage story with potential accelerated approval on the near-term horizon. PARP1-selective inhibitors EIK1003 and EIK1004 are advancing with the potential to expand a validated mechanism of action beyond current settings.The company maintains a strong current ratio of 8.8, though InvestingPro notes the biotech is quickly burning through cash—typical for development-stage companies with multiple ongoing trials. InvestingPro offers 3 additional key tips for EIKN investors evaluating the risk-reward profile. The earlier-stage pipeline, stemming from Eikon’s super resolution microscopy platform, represents longer-term optionality. JPMorgan views the company as holding multiple levers for upsi...
Read full article at source